Showing 8251-8260 of 21409 results for "".
Juvenile Diabetes Research Foundation
https://reachmd.com/programs/clinicians-roundtable/juvenile-diabetes-research-foundation/1876/Join Dr. Lou Philipson from the University of Chicago and Amy Franze, the Executive Director of the Illinois JDRF, to discuss type 1 diabetes.The Diabetic Investor
https://reachmd.com/programs/clinicians-roundtable/the-diabetic-investor/1642/Join host Larry Kaskel interview David Kliff, a diabetic himself and the publisher of the Diabetic Investor. Should you invest in the Diabetes Sector? What drug companies will pick up the Avandia business? Find out in this segment.Implications of the ACCORD, ADVANCE and VA Diabetes Trials
https://reachmd.com/programs/diabetes-discourse/implications-of-the-accord-advance-and-va-diabetes-trials/5006/The ACCORD, ADVANCE and VA Diabetes Trials seem to indicate that there is no real benefit of intensive glycemic control on cardiovascular events in patients with type 2 diabetes. Join host Dr. Steven Edelman and his guest, executive director of the International Diabetes Center at Park Nicollet, Dr.New Treatments for Peripheral Diabetic Neuropathy
https://reachmd.com/programs/diabetes-discourse/new-treatments-for-peripheral-diabetic-neuropathy/4691/Diabetic peripheral neuropathy remains one of the most common complications in diabetes. Because type 2 diabetes often goes undiagnosed for many years, it is common for patients to present with some degree of neuropathy. Our guest, podiatrist, specializing in diabetic foot problems, Dr. Ingrid KruseAnticoagulation Reversal Decisions in Cardiothoracic Surgery: Case-Based Insights
https://reachmd.com/programs/heart-matters/anticoagulation-reversal-cardiothoracic-surgery/57167/In cardiothoracic surgery, the need for anticoagulation reversal can arise quickly, and the path forward isn’t always clear. In this case-based discussion with Dr. Brian McDonough, Dr. Akshay Kumar shares his perspective on making anticoagulation reversal decisions across a range of urgentInpatient and Outpatient Recommendations for Diabetes
https://reachmd.com/programs/diabetes-discourse/inpatient-and-outpatient-recommendations-for-diabetes/6461/The transition from hospital to home for patients with diabetes can be challenging, from glycemic targets, guidelines for initiating insulin therapy, the various types of insulin and oral agents to general nutrition. What are the current recommendations for the transition from hospital to home for pThe Benefits of Moderate Weight Loss in Diabetes
https://reachmd.com/programs/diabetes-discourse/the-benefits-of-moderate-weight-loss-in-diabetes/5344/Patients with type 2 diabetes struggle to lose or maintain weight, especially with particular therapies. What are some of the successful therapeutic interventions available for overweight patients with type 2 diabetes? What are the potential health effects of the loss of even 5 to 10 pounds for thesPedophilia -Types and Classifications
https://reachmd.com/programs/clinicians-roundtable/pedophilia-types-and-classifications/408/Dr. Ryan Hall, a senior resident from the Department of Psychiatry and Behavioral Sciences at John Hopkins University defines pedophilia and classifies distinctions between the different types.The Challenges of Diagnosing Diabetes in Children
https://reachmd.com/programs/diabetes-discourse/the-challenges-of-diagnosing-diabetes-in-children/4688/The incidence of diabetes is increasing per year in the US and globally. The trend data suggests that obesity may be driving autoimmune beta cell failure. Some have questioned whether excess obesity or adiposity might be playing a role in this increased incidence of type 1 diabetes or whether healthLong Term Efficacy and Safety of Laronidase for MPS I
https://reachmd.com/programs/clinicians-roundtable/long-term-efficacy-and-safety-of-laronidase-for-mps-i/4755/Host Dr. Bruce Bloom welcomes Dr. Emil Kakkis, an advisor at BioMarin Pharmaceutical Inc. and author of numerous published articles on mucopolysaccharidosis I, or MPS I, to discuss current treatment options. They discuss the benefits and risks of enzyme replacement therapy with laronidase. Don't mis